Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual
thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by
IV infusion of mutant pro-urokinase against usual treatment with IV alteplase in patients
presenting with ischemic stroke.
Phase:
Phase 2
Details
Lead Sponsor:
Erasmus Medical Center Nadinda van der Ende
Collaborator:
DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution.